- No public price. The site shows no plan, billing period or trial.
- Not disclosed
- Not disclosed
- —
- —
- SG
Pathology
Qritive Pantheon
by Qritive · SG
Pantheon is a CE-marked (April 2021) digital pathology platform. Its QAi AI modules were research use only at the 2023 launch.
On this page
5/100Tracked
- Regulatory & Compliance0/28
No FDA clearance listed
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength0/28.8
No peer-reviewed coverage
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/18
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/21
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
Pantheon is a CE-marked (April 2021) digital pathology platform. Its QAi AI modules were research use only at the 2023 launch.
No public price. The site shows no plan, billing period or trial.
Bottom line
Pantheon is a digital pathology platform from Qritive of Singapore, and the AI sits in separate QAi modules on top of it. The platform carries a CE mark, and the AI prostate module launched in March 2023 as a research or laboratory-developed tool. The FDA's 510(k) records list nothing for Qritive. Qritive raised $7.5 million in January 2023, and no price is public.
What are Pantheon and QAi?
Tracxn and BioSpectrum describe Pantheon as a CE-marked, vendor-agnostic digital pathology platform. It digitises the pathology laboratory workflow, supports telepathology and hosts AI analysis of whole-slide images.
QAi Prostate, the AI module for prostate cancer diagnosis, was launched in March 2023, per BioSpectrum Asia. It came out as research use or as a laboratory-developed test, without a CE mark or FDA clearance.
What is the regulatory status?
According to Tracxn, Pantheon received its CE mark on 15 April 2021 and a Singapore HSA Class A registration on 23 July 2020. Those are platform registrations. QAi Prostate launched without a CE mark.
In the US, the FDA's 510(k) records list no clearance for Qritive.
Who is behind it, and how well funded?
Qritive Pte. Ltd. is based in Singapore with offices in the US and India. MassMutual Ventures led a $7.5 million round in January 2023 with SEEDS Capital and Exfinity, as TechNode reported. Tracxn puts total funding at $7.75 million and PitchBook at $9.7 million.
Which labs does it fit?
A pathology laboratory that wants to digitise its slide workflow and keep its choice of scanner, since the platform is described as vendor-agnostic. Telepathology support suits a lab network that shares cases across sites.
How is Pantheon priced?
Qritive publishes no price.
The verdict
Pantheon suits a laboratory that wants a vendor-agnostic, CE-marked platform to digitise slides and share cases. A laboratory that wants the AI modules for routine diagnosis has a CE mark for the platform only and a prostate module that launched as research use. In the US the platform has no FDA clearance on record.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Quote only | — | — | No public price. The site shows no plan, billing period or trial. |
Source: vendor pricing page. Last checked October 15, 2026.
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
No public price on the Tempus pages.|FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer)
PathAI AISight
by PathAI
Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.
No public price. Billing period, trial and refund not stated.|FDA 510(k)
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
No public price. Demo request only.|FDA 510(k) / SOC 2 Type II (vendor announcement, 2025-12-03)
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
No public price. Sold to laboratories and health systems on enterprise contracts.|FDA 510(k)